Haemonetics (HAE)
NYSEHealth CareMedical - DevicesSnapshot 2026-09-04
$102.92+0.07%
Close 2026-09-04 · 1-day change
NYSEHealth CareMedical - DevicesSnapshot 2026-09-04
QuarterlyIQ Insights · HAE
Income statement, balance sheet, and cash flow — annual and quarterly history, as reported.
Figures in millions of USD, except per-share and ratios.
| TTM | Mar 2026 | Mar 2025 | Mar 2024 | Mar 2023 | Mar 2022 | Mar 2021 | Mar 2020 | Mar 2019 | Mar 2018 | Mar 2017 | Mar 2016 | Mar 2015 | Mar 2013 | Mar 2012 | Mar 2011 | Mar 2010 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenues | |||||||||||||||||
| Revenues | 1,352.0 | 1,334.0 | 1,360.8 | 1,309.1 | 993.2 | 870.5 | — | 988.5 | 967.6 | 903.9 | 886.1 | 908.8 | 910.4 | 938.5 | 892.0 | 727.8 | 676.7 |
| Total Revenues | — | — | — | — | — | — | — | — | — | — | — | — | 910.4 | 938.5 | 892.0 | 727.8 | — |
| Cost of Revenues | 553.9 | 546.4 | 611.9 | 617.5 | 487.7 | 472.6 | — | 504.0 | 550.0 | — | — | — | — | — | — | — | — |
| Gross Profit | 798.1 | 787.6 | 749.0 | 691.5 | 505.5 | 397.8 | — | 484.5 | 417.5 | 411.9 | 378.5 | 405.9 | 434.4 | 468.4 | 428.1 | 369.2 | 355.2 |
| Operating Expenses & Income | |||||||||||||||||
| Selling, General & Admin | 450.6 | 442.4 | 436.8 | 431.8 | 340.1 | 275.2 | — | 282.0 | 273.5 | 316.5 | 301.7 | 317.2 | 337.2 | 366.0 | 323.1 | 243.7 | 213.9 |
| R&D Expenses | 59.7 | 59.8 | 62.7 | 54.4 | 46.8 | 32.9 | — | 30.9 | 35.7 | 39.2 | 37.6 | 45.0 | 54.2 | 54.2 | 44.4 | 36.8 | 32.7 |
| Operating Income | 160.3 | 156.7 | 221.8 | 164.9 | 80.8 | 89.7 | — | 103.4 | 83.5 | 56.2 | (19.4) | (43.9) | 40.5 | 46.4 | 56.4 | 88.8 | 110.5 |
| Earnings from Continuing Operations | |||||||||||||||||
| Interest Expense | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | 0.0 |
| Interest & Investment Income | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | 0.4 |
| Net Interest Expenses | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | (0.4) |
| Asset Writedown | — | 86.5 | 2.4 | 10.4 | 8.0 | 22.0 | — | 50.6 | 21.2 | 2.7 | 75.3 | 101.2 | 5.9 | 2.6 | 4.2 | 0.0 | — |
| EBT, Incl. Unusual Items | 130.4 | 128.0 | 212.1 | 151.9 | 63.6 | 72.9 | — | 87.2 | 73.6 | 59.6 | (27.5) | (53.4) | 31.2 | 36.4 | 49.9 | 89.5 | 110.1 |
| Income Tax Expense | 34.1 | 30.7 | 44.4 | 34.3 | 20.3 | (6.6) | — | 10.6 | 18.6 | 14.1 | (1.2) | 2.2 | 14.3 | 1.3 | 11.1 | 22.6 | 30.1 |
| Net Income | |||||||||||||||||
| Net Income | (0.9) | 97.3 | 167.7 | 117.6 | 43.4 | 79.5 | — | 76.5 | 55.0 | 45.6 | (26.3) | (55.6) | 16.9 | 35.1 | 38.8 | 66.9 | 80.0 |
| Per Share | |||||||||||||||||
| Basic EPS | (0.02) | 2.06 | 3.33 | 2.32 | 0.85 | 1.57 | — | 1.51 | 1.07 | 0.86 | (0.51) | (1.09) | 0.33 | 0.68 | 0.76 | 1.32 | 1.59 |
| Diluted EPS | (0.02) | 2.05 | 3.31 | 2.29 | 0.84 | 1.55 | — | 1.48 | 1.04 | 0.85 | (0.51) | (1.09) | 0.32 | 0.67 | 0.74 | 1.30 | 1.56 |
| Revenue per Share | 29.58 | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — |
| Basic Weighted Avg Shares | 45.4 | 47.2 | 50.3 | 50.7 | 51.0 | 50.7 | — | 50.7 | 51.5 | 52.8 | 51.5 | 50.9 | 51.5 | 51.6 | 51.3 | 50.7 | 50.2 |
| Diluted Weighted Avg Shares | 45.7 | 47.4 | 50.7 | 51.4 | 51.4 | 51.3 | — | 51.8 | 52.9 | 53.5 | 51.5 | 50.9 | 52.1 | 52.4 | 52.3 | 51.6 | 51.2 |
| Supplemental | |||||||||||||||||
| EBITDA | — | 268.5 | 337.4 | 262.1 | 178.5 | 174.0 | — | 213.6 | 193.0 | 145.4 | 70.4 | 46.0 | 126.6 | 128.2 | 121.9 | 138.7 | 158.7 |
| EBIT | 160.3 | 156.7 | 221.8 | 164.9 | 80.8 | 89.7 | — | 103.4 | 83.5 | 56.2 | (19.4) | (43.9) | 40.5 | 46.4 | 56.4 | 88.8 | 110.5 |
| Effective Tax Rate | 26.2% | — | — | — | 31.8% | -9.0% | — | 12.2% | 25.3% | 23.6% | 4.4% | -4.0% | 45.8% | 3.4% | 22.2% | 25.3% | 27.3% |
Not investment advice. Scores describe historical and current data; they are not forecasts of future returns. Consult a licensed advisor before making investment decisions.